Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

ATH-1105 is the Company's novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to ...

The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...

Clinical pipeline: 67 distinct antiviral compounds are currently in active clinical development, with 22 approved compounds ...

Global antiviral R&D is slowing when the world can least afford it, new analysis shows CAMBRIDGE, Mass., May 5, 2025 /PRNewswire/ -- The INTREPID Alliance today released the fourth edition ...

the Company may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or we may experience ...

His responsibilities include guiding candidate selection and advancing preclinical studies including CMC, drug safety evaluation and translational biomarkers to support clinical development.

Activist Commentary: Elliott is a very successful and astute activist investor. The firm's team includes analysts from ...

Finally, Werewolf has been making significant progress towards nominating its first INDUCER T cell engager development candidate in the second quarter of 2025, with preclinical data demonstrating ...

The projected timeline to identify a preclinical measles mAb candidate in 2025 demonstrates the company's commitment to advancing its research and development efforts promptly. The press release ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.